Karuna Therapeutics in the spotlight

Fundamental & technical deep-dive on science and stock

Following up on our continued coverage of Karuna (KRTX) from last month, yesterday the Company reported data on the third positive registrational trial, announcing that the trial met its primary endpoint. With three positive registrational trials reported for schizophrenia, Karuna is well-positioned to win FDA approval with a planned NDA by mid-2023 and…